Community-acquired pneumonia (CAP) severity tool. Used in Australian EDs and general practice to guide home vs hospital decisions.
CURB-65 is a validated clinical severity score for community-acquired pneumonia (CAP), developed by Lim et al. (Thorax 2003) and referenced in British Thoracic Society (BTS) and NICE pneumonia guidance.
Each letter represents one variable worth 1 point: Confusion (new), Urea >7 mmol/L, Respiratory rate ≥30/min, Blood pressure low (systolic <90 or diastolic ≤60 mmHg), and age ≥65. Total score ranges from 0–5.
In the original study (Lim et al. 2003), 30-day mortality rose as the score increased. Figures are not reproduced here; see the paper.
| CURB-65 score | Band (NICE NG250, 2025) |
|---|---|
| 0–1 | Low risk (usually) |
| 2 | Moderate risk |
| 3 or more | High risk |
Source: NICE NG250 (2025). Score variables: Lim WS et al. Thorax 2003;58:377–382. Where and how a person is treated is a decision for their treating clinician; this table is information only.
In CURB-65, confusion means new disorientation in person, place or time, not pre-existing dementia or chronic cognitive impairment. Some versions define it as an Abbreviated Mental Test Score (AMTS) of 8 or less out of 10.
Source: Lim WS et al. Thorax 2003;58:377–382.
CURB-65 is validated for community-acquired pneumonia (CAP) in adults. It is not validated for:
CURB-65 does not capture several important clinical factors. Always consider:
If urea is not available, a 4-variable version without urea (CRB-65) is used. NICE NG250 describes its primary-care bands as 0 low risk, 1–2 moderate risk, and 3–4 high risk.
This page does not give treatment or dosing information. Treatment choices are set out in current clinical guidelines such as Therapeutic Guidelines: Antibiotic (eTG, Australia; subscription) and NICE NG250. Dosing and drug choice depend on the individual and are for the treating clinician.